Further experimental and prospectively-designed studies should be performed to clarify the influences of these two novel adipokines, progranulin and CTRP3, on the pathogenesis and outcomes of chronic metabolic disorders and cardiovascular disease. This evidence concerns the gene GRN and cardiovascular disorder.